A 57-year-old woman, with long-standing hypogonadism secondary to irradiation of the ovaries, was found to have a pituitary tumor which was removed and investigated by histology, immunocytology and electron microscopy. Histologically, the tumor corresponded to a chromophobe, slightly PAS positive adenoma and the immunoperoxidase stain revealed the presence of both FSH and LH in the cytoplasm of the adenoma cells. The structural features of the adenoma cells resembled those of FSH cells in the nontumorous adenohypophysis. We thus believe that pituitary adenomas consisting of gonadotrophin-producing cells occur and that these may produce both FSH and LH. The relation between the gonadotrophin-producing adenoma and the preceding hypogonadism is uncertain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02109828 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic diagnosis of endocrine disorders in Cyprus through the Cyprus Institute of Neurology and Genetics: an ENDO-ERN Reference Center.
Orphanet J Rare Dis
April 2024
Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Article Synopsis
- The report highlights the activities of the Molecular Genetics-Function and Therapy (MGFT) department at the Cyprus Institute of Neurology and Genetics, emphasizing its role as a Reference Center for the European Network on Rare Endocrine Conditions (Endo-ERN).
- Over 15 years of collaboration has resulted in more than 2000 genetic tests performed for diagnosing rare inherited endocrine disorders, with significant findings related to various genetic variants associated with conditions like Congenital Adrenal Hyperplasia (CAH) and Multiple Endocrine Neoplasia (MEN).
- The MGFT has also developed a diagnostic and research program focusing on premature puberty, particularly the role of the MKRN3 gene, aiming to enhance healthcare for patients with rare endocrine
Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
Front Pharmacol
July 2023
Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
Testosterone is an essential sex hormone in maintaining masculine characteristics, which is prescribed for male hypogonadism as testosterone replacement treatment (TRT). Herein, we investigated long-standing controversies about the association between TRT and major adverse cardiovascular events (MACEs), based on real world adverse event (AE) reports, registered in the Food and Drug Administration Adverse Event Reporting System (FAERS). Publicly available FAERS data from 1 January 2004 to 31 December 2022 were retrieved from the Food and Drug Administration (FDA) website.
View Article and Find Full Text PDFCase Report: Successful Outcome of Primary Infertility with Multidrug Therapy in a Long-Standing Case of Hypogonadism Resulting from Lepromatous Leprosy: Shattering the Dogma of Irreversible Infertility in Leprosy.
Am J Trop Med Hyg
October 2021
Department of Pathology, ABVIMS and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
We present a case of primary infertility with features of hypogonadism in a male patient with lepromatous leprosy who had remained undiagnosed for 3 years. On investigation, azoospermia and deranged gonadotropin levels with normal serum testosterone were noted and the patient was initiated on multibacillary-multidrug therapy with the primary aim of treating the disease. Although the cutaneous lesions improved within 6 weeks, remarkably infertility was reversed in 2 months-with concomitant normalization of luteinizing hormone, follicle stimulating hormone, and sperm count-an outcome that was unexpected.
View Article and Find Full Text PDFTraumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment.
Front Endocrinol (Lausanne)
December 2021
Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy.
Traumatic brain injury (TBI)-related hypopituitarism has been recognized as a clinical entity for more than a century, with the first case being reported in 1918. However, during the 20 century hypopituitarism was considered only a rare sequela of TBI. Since 2000 several studies strongly suggest that TBI-mediated pituitary hormones deficiency may be more frequent than previously thought.
View Article and Find Full Text PDFProlactinomas in males: any differences?
Pituitary
February 2020
Institute of Endocrinology and Metabolism, Rabin Medical Center - Beilinson Hospital, 4941492, Petach Tikva, Israel.
Context: Prolactinomas in men are usually large and invasive, presenting with signs and symptoms of hypogonadism and mass effects, including visual damage. Prolactin levels are high, associated with low testosterone, anemia, metabolic syndrome and if long-standing also osteoporosis.
Results: Medical treatment with the dopamine agonist, cabergoline, became the preferred first-line treatment for male prolactinomas as well as for giant tumors, leading to prolactin normalization in ~ 80% of treated men, and tumor shrinkage, improved visual fields and recovery of hypogonadism in most patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!